14 documents found, page 1 of 2
Genetic determinants for prediction of outcome of patients with papillary thyro...
Póvoa, AA; Teixeira, E; Bella-cueto, MR; Batista, R; Pestana, A; Melo, M; Alves, T; Pinto, M; Sobrinho-Simões, M; Maciel, J; Soares, PPapillary thyroid carcinoma (PTC) usually presents an excellent prognosis, but some patients present with aggressive metastatic disease. BRAF, RAS, and TERT promoter (TERTp) genes are altered in PTC, and their impact on patient outcomes remains controversial. We aimed to determine the role of genetic alterations in PTC patient outcomes (recurrent/persistent disease, structural disease, and disease-specific mort...
Indoor environmental quality in households of families with infant twins under ...
Gabriel, MF; Felgueiras, F; Batista, R; Ribeiro, C; Ramos, E; Mourão, Z; de Oliveira Fernandes, EExposure to air pollution in early years can exacerbate the risk of noncommunicable diseases throughout childhood and the entire life course. This study aimed to assess temperature, relative humidity (RH), carbon dioxide (CO2) and monoxide (CO), particulate matter (PM2.5, PM10), ultrafine particles, nitrogen dioxide (NO2), ozone (O3), formaldehyde, acetaldehyde and volatile organic compounds (VOC) levels in the...
Clinical validation of a urine test (uromonitor-V2(®)) for the surveillance of ...
Sieverink, CA; Batista, R; Prazeres, H; Vinagre, J; Sampaio, C; Leão, RR; Máximo, V; Alfred Witjes, J; Soares, PThe costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder cancer (NMIBC) drives the development of new methods that may alternate with regular cystoscopy and urine cytology. The Uromonitor-V2® is a new urine-based assay in the detection of hotspot mutations in three genes (TERT, FGFR3, and KRAS) for evaluation of disease recurrence. The aim of this study was to investigate...
Comprehensive assessment of tert mRNA expression across a large cohort of benig...
Pestana, A; Batista, R; Celestino, R; Canberk, S; Sobrinho-Simões, M; Soares, PThe presence of TERT promoter (TERTp) mutations in thyroid cancer have been associated with worse prognosis features, whereas the extent and meaning of the expression and activation of TERT in thyroid tumours is still largely unknown. We analysed frozen samples from a series of benign and malignant thyroid tumours, displaying non-aggressive features and low mutational burden in order to evaluate the presence of...
Biomarkers for bladder cancer diagnosis and surveillance: A comprehensive review
Batista, R; Vinagre, N; Meireles, S; Vinagre, J; Prazeres, H; Leão, R; Máximo, V; Soares, PBladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by in...
TERT promoter mutation as a potential predictive biomarker in BCG-treated bladd...
Batista, R; Lima, L; Vinagre, J; Pinto, V; Lyra, J; Máximo, V; Santos, L; Soares, PTelomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Methods — 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, ...
Prognostic significance of RAS mutations and P53 expression in cutaneous squamo...
Campos, MA; Macedo, S; Fernandes, MS; Pestana, A; Pardal, J; Batista, R; Vinagre, J; Sanches, A; Baptista, A; Lopes, JM; Soares, PTP53 is considered the most commonly-altered gene in cutaneous squamous cell carcinoma (cSCC). Conversely, RAS mutations have been reported in a low percentage of cSCC. The objective of our study was to evaluate the frequency of p53 expression and RAS mutations in cSCC and correlate them with clinicopathological features and patient outcome. We performed immunohistochemistry for p53 and genetic profiling for RA...
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence ...
Batista, R; Vinagre, J; Prazeres, H; Sampaio, C; Peralta, P; Conceição, P; Sismeiro, A; Leão, R; Gomes, A; Furriel, F; Oliveira, C; Torres, JNBladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most prevalent cancer worldwide. Of all newly diagnosed patients with BC, 70–75% will present disease confined to the mucosa or submucosa, the non-muscle-invasive BC (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to high rate of recurrence, patients are submitted to an i...
NIS expression in thyroid tumors, relation with prognosis clinicopathological a...
Tavares, C; Coelho, MJ; Eloy, C; Melo, M; Rocha, AG; Pestana, A; Batista, R; Ferreira, LB; Rios, E; Selmi-Ruby, S; Cavadas, B; Pereira, LThyroid cancer therapy is based on surgery followed by radioiodine treatment. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the SLC5A5 gene), that is functional only when targeted to the cell membrane. We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis. NIS ...
mTOR pathway in papillary thyroid carcinoma: Different contributions of mTORC1 ...
Tavares, C; Eloy, C; Melo, M; Rocha, AG; Pestana, A; Batista, R; Ferreira, LB; Rios, E; Sobrinho-Simões, M; Soares, PThe mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC). We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features. The distinct behavior...